Home » News » Nephrology » Hyperkalemia
Hyperkalemia
Guidelines support the use of RAASi at the maximum tolerated dose in patients with CKD and heart failure.
Study findings do not support eliminating potassium-containing foods from the diet to manage hyperkalemia.
Hyperkalemia is associated with increased health care resource utilization.
SGLT2 inhibitors and MRAs might provide complementary effects for organ protection, according to investigators.
Trimethoprim-sulfamethoxazole is mostly excreted through the kidneys, and it can cause hyperkalemia by reducing potassium excretion.
Tacrolimus exposure was reduced by approximately one-third when it was co-administered with the potassium binder sodium zirconium cyclosilicate, investigators reported.
Stopping renin-angiotensin-aldosterone inhibitors after hyperkalemia may offset their potential clinical benefits, according to investigators.
Investigators report a low incidence of hypokalemia and hypomagnesemia after a single dose of patiromer monotherapy.
Potassium binders historically have been used short term or intermittently.
Discontinuation of RAAS inhibitors is often the first approach to manage hyperkalemia.
Load More
Open
Next post in Hyperkalemia
Close
Close more info about Suboptimal RAASi Therapy After Hyperkalemia Ups Cardiorenal Risks
Loading...
Close more info about Suboptimal RAASi Therapy After Hyperkalemia Ups Cardiorenal Risks
Loading...